How Wegovy and Mounjaro work — mechanism comparison
Wegovy (semaglutide) and Mounjaro (tirzepatide) belong to overlapping but distinct drug classes. Both work via the incretin (gut-hormone) pathway, but they have different molecular targets:
- Wegovy (semaglutide) — GLP-1 receptor agonist
- Mounjaro (tirzepatide) — GLP-1 receptor agonist
This mechanistic difference matters because it determines: efficacy (how much weight loss / blood-sugar control you can expect), side-effect profile, dosing schedule, and which patients may benefit most. Read more in our Wegovy mechanism guide and Mounjaro mechanism guide.
Efficacy head-to-head
In their respective pivotal trials, mean body-weight reduction reached:
- Wegovy: 14.9% at 68 weeks (trial: STEP-1)
- Mounjaro: no weight-loss trial of its own
Side-by-side radar: Wegovy vs Mounjaro
Editorial scoring across 5 dimensions, overlaid. Higher area = better overall fit.
| Axis | Wegovy | Mounjaro |
|---|---|---|
| Efficacy | 8 | 10 |
| Convenience | 9 | 9 |
| Affordability | 6 | 5 |
| Tolerance | 5 | 6 |
| Evidence | 10 | 6 |
Higher score = better on that axis. Editorial scoring; not a substitute for prescriber judgment.
Side effects compared
Both drugs share the GLP-1 class side-effect profile — primarily gastrointestinal (nausea, diarrhea, constipation, vomiting) in early treatment, fading as the body adapts. Both carry the FDA boxed warning for thyroid C-cell tumors and contraindications for personal/family history of medullary thyroid carcinoma.
Side-effect rate comparator
Trial-derived adverse-event rates with placebo delta. Sourced from FDA-approved labels for each drug. Most sources omit placebo rates entirely.
| Adverse event | Wegovy | Mounjaro |
|---|---|---|
| Nausea | 44%(placebo 16%) +28.0 pp vs placebo | 18%(placebo 4%) +14.0 pp vs placebo |
| Diarrhea | 30%(placebo 16%) +14.0 pp vs placebo | 17%(placebo 9%) +8.0 pp vs placebo |
| Vomiting | 24%(placebo 6%) +18.0 pp vs placebo | 9%(placebo 2%) +7.0 pp vs placebo |
| Constipation | 24%(placebo 11%) +13.0 pp vs placebo | 7%(placebo 1%) +6.0 pp vs placebo |
| Abdominal pain | 20%(placebo 10%) +10.0 pp vs placebo | 5%(placebo 4%) +1.0 pp vs placebo |
| Headache | 14%(placebo 10%) +4.0 pp vs placebo | — |
| Fatigue | 11%(placebo 5%) +6.0 pp vs placebo | — |
| Decreased appetite | — | 11%(placebo 1%) +10.0 pp vs placebo |
| Dyspepsia | — | 5%(placebo 3%) +2.0 pp vs placebo |
Patients who tolerate one GLP-1 well often (but not always) tolerate another. Switching between class members typically requires re-titration regardless of prior tolerability. See full side-effect breakdowns for Wegovy and Mounjaro.
Dosing schedule comparison
Both medications use step-up titration to minimize side effects, but the schedule details differ:
Wegovy
- Weeks 1–4: 0.25 mg/week
- Weeks 5–8: 0.5 mg/week
- Weeks 9–12: 1 mg/week
- Weeks 13–16: 1.7 mg/week
- Week 17+: 2.4 mg/week
Mounjaro
- Weeks 1–4: 2.5 mg/week
- Weeks 5–8: 5 mg/week
- Weeks 9–12: 7.5 mg/week
- Weeks 13–16: 10 mg/week
- Weeks 17–20: 12.5 mg/week
- Week 21+: 15 mg/week
See full titration guides for Wegovy dosing and Mounjaro dosing.
Cost comparison
Cost differences between Wegovy and Mounjaro depend on insurance coverage, manufacturer savings programs, and partner-network pricing — not just retail price.
- Average retail price (Wegovy): $1349/month
- Average retail price (Mounjaro): $1069/month
- Wegovy savings card: as low as $25/month for eligible commercial-insured
- Mounjaro savings card: as low as $25/month for eligible commercial-insured
For most patients, the actual out-of-pocket cost is driven by: (1) what your insurance formulary tier places Wegovy vs Mounjaro, (2) whether you qualify for manufacturer savings cards (commercial insurance only), and (3) telehealth partner network availability. Full cost breakdowns: Wegovy cost guide · Mounjaro cost guide.
Which one to choose — decision factors
There's no single «better» drug — the right choice depends on individual circumstances. The key decision factors:
Choose Wegovy if…
- Your insurance covers it but not Mounjaro
- Your prescriber has more experience with it
- You prefer drugs with longer post-market track record
Choose Mounjaro if…
- Your insurance covers it but not Wegovy
- Your prescriber has more experience with it
Switching from Wegovy to Mounjaro (or vice versa)
Switching between Wegovy and Mounjaro (different active ingredients) typically requires restarting titration from the lowest doseof the new drug. Different molecules have different potencies — your tolerated dose of one doesn't map directly to the other. Plan for:
- Return of titration-period side effects (nausea, GI) for 2-4 weeks on restart
- Possibly temporary weight regain during the transition
- Fresh insurance prior-authorization (different drug = new PA)
- 2-4 weeks for the new drug to reach steady-state plasma levels
FAQ — Wegovy vs Mounjaro
Are Wegovy and Mounjaro the same drug?
No — they contain different active ingredients (semaglutide and tirzepatide). They belong to similar drug classes (GLP-1 family) but work via slightly different molecular targets.
Which is more effective for weight loss, Wegovy or Mounjaro?
Wegovy produced about 14.9% average weight loss in STEP-1. Mounjaro has no weight-loss trial of its own to set against it, so the two cannot be ranked on weight loss.
Can I take Wegovy and Mounjaro together?
No. Combining two GLP-1 receptor agonists provides no added benefit and dramatically increases side-effect risk. Standard practice is to switch between them, not combine them.
Which has fewer side effects, Wegovy or Mounjaro?
Both mostly cause stomach side effects. In their labels' placebo-controlled tables, nausea was reported by 44% on Wegovy (placebo 16%) and 18% on Mounjaro (placebo 4%). The trials used different doses and populations, so this is not a head-to-head comparison.
Will my insurance cover Wegovy but not Mounjaro?
Often the coverage differs. Insurance formularies are negotiated separately per drug — Wegovy may be on Tier 2 of your plan while Mounjaro is Tier 4 or excluded. Check your formulary before assuming both are equally accessible.
Editorial comparison based on FDA prescribing information and published clinical data. Not a substitute for prescriber consultation. Full medical disclaimer.